Literature DB >> 28500433

The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Yang Wang1, Huifang Zhou2, Xianqun Fan3.   

Abstract

Thyroid-associated orbitopathy (TAO) is an inflammatory autoimmune disorder. The most serious complication of TAO is dysthyroid optic neuropathy (DON), which can lead to permanent vision loss because of volume expansion in the orbital apex. Orbital radiation therapy (ORT) is an anti-inflammatory treatment used in the treatment of active TAO. Clinical studies support radiotherapy as having a modest effect on DON, and early radiotherapy may protect against disease progression to DON. Current studies suggest that radiotherapy is generally safe. However, risks still exist in some cases. The possible effects of radiotherapy on TAO, especially complicated with DON, are reviewed. The effects of radiotherapy on DON are not completely known, and evidence from standardized, prospective, and multicenter clinical trials is still lacking.

Entities:  

Keywords:  dysthyroid optic neuropathy; orbital radiation therapy; thyroid-associated orbitopathy

Mesh:

Year:  2017        PMID: 28500433     DOI: 10.1007/s11684-017-0528-5

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  49 in total

Review 1.  Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.

Authors:  John H Lazarus
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

2.  Compressive Optic Neuropathy in Thyroid Eye Disease.

Authors:  Preeti Thyparampil; Michael T Yen
Journal:  Int Ophthalmol Clin       Date:  2016

3.  Thyroid eye disease.

Authors:  Petros Perros; Christopher Neoh; Jane Dickinson
Journal:  BMJ       Date:  2009-03-06

Review 4.  Radiation Retinopathy 15 Years after Orbital Irradiation for Thyroid Orbitopathy.

Authors:  K Hurtikova; G von Arx; N Fichter; H Gerding
Journal:  Klin Monbl Augenheilkd       Date:  2016-04-26       Impact factor: 0.700

5.  Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.

Authors:  Pari N Shams; Roy Ma; Tom Pickles; Jack Rootman; Peter J Dolman
Journal:  Am J Ophthalmol       Date:  2014-02-26       Impact factor: 5.258

Review 6.  Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy.

Authors:  Terry J Smith; Chieh Chih Tsai; Mei-Ju Shih; Shanli Tsui; Beiling Chen; Rui Han; Vibha Naik; Chris S King; Chris Press; Shweta Kamat; Robert A Goldberg; Richard P Phipps; Raymond S Douglas; Andrew G Gianoukakis
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

7.  Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy.

Authors:  Dennis M Robertson; Helmut Buettner; Colum A Gorman; James A Garrity; Vahab Fatourechi; Rebecca S Bahn; Ivy A Petersen; Scott L Stafford; John D Earle; Glenn S Forbes; Robert W Kline; Erik J Bergstralh; Kenneth P Offord; Diana M Rademacher; Nancy M Stanley; George B Bartley
Journal:  Arch Ophthalmol       Date:  2003-05

8.  Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.

Authors:  P Perros; A L Crombie; J N Matthews; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1993-04       Impact factor: 3.478

9.  A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Authors:  Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

10.  Effect of radiation therapy on intraocular pressure in patients with Graves' orbitopathy.

Authors:  David J Russell; Jonathan J Dutton; Rosalinda L Baca
Journal:  Orbit       Date:  2013-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.